Abstract
The expression of the drug resistance (DR) mediators P-glycoprotein (P-gp) and the metallothioneins (MT) was assessed immunohistochemically in biopsy material from patients with high-grade malignant osteosarcoma (OS). No significant difference was found in survival rate between expressors of both P-gp and MT and non-expressors. Thus, it was concluded that lack of expression of these two drug resistance-related proteins does not appear to confer any advantage in terms of patient survival in osteosarcoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shnyder, S., Hayes, A., Pringle, J. et al. P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma. Br J Cancer 78, 757–759 (1998). https://doi.org/10.1038/bjc.1998.573
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.573
This article is cited by
-
Zinc chelation: a metallothionein 2A’s mechanism of action involved in osteosarcoma cell death and chemotherapy resistance
Cell Death & Disease (2013)
-
Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone
British Journal of Cancer (2010)
-
Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi
European Journal of Nuclear Medicine and Molecular Imaging (2007)
-
Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs–pRb2/p130 complexes
Oncogene (2003)
